Page 23 - 2021_06-Haematologica-web

The post-HCT microbiome: effects and targeted therapy
etic stem cell transplantation. Clin Infect
Dis. 2012;55(7):905-914.
28. Ubeda C, Taur Y, Jenq RR, et al.
Vancomycin-resistant Enterococcus domi- nation of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest. 2010;120(12):4332-4341.
29. Taur Y, Coyte K, Schluter J, et al. Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. Sci Transl Med. 2018;10(460):eaa9489.
30. Peled JU, Gomes ALC, Devlin SM, et al. Microbiota as predictor of mortality in allo- geneic hematopoietic-cell transplantation. N Engl J Med. 2020;382(9):822-834.
31.Weber D, Jenq RR, Peled JU, et al. Microbiota disruption induced by early use of broad-spectrum antibiotics is an inde- pendent risk factor of outcome after allo- geneic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(5):845-852.
32.Shono Y, Docampo MD, Peled JU, et al. Increased GVHD-related mortality with broad-spectrum antibiotic use after allo- geneic hematopoietic stem cell transplanta- tion in human patients and mice. Sci Transl Med. 2016;8(339):339ra371.
33. Simms-Waldrip TR, Sunkersett G, Coughlin LA, et al. Antibiotic-induced depletion of anti-inflammatory clostridia is associated with the development of graft-versus-host disease in pediatric stem cell transplantation patients. Biol Blood Marrow Transplant. 2017;23(5):820-829.
34. Lee SE, Lim JY, Ryu DB, et al. Alteration of the intestinal microbiota by broad-spectrum antibiotic use correlates with the occurrence of intestinal graft-versus-host disease. Biol Blood Marrow Transplant. 2019;25(10): 1933-1943.
35.van Vliet MJ, Tissing WJ, Dun CA, et al. Chemotherapy treatment in pediatric patients with acute myeloid leukemia receiving antimicrobial prophylaxis leads to a relative increase of colonization with potentially pathogenic bacteria in the gut. Clin Infect Dis. 2009;49(2):262-270.
36. Zwielehner J, Lassl C, Hippe B, et al. Changes in human fecal microbiota due to chemotherapy analyzed by TaqMan-PCR, 454 sequencing and PCR-DGGE fingerprint- ing. PLoS One. 2011;6(12):e28654.
37. Biagi E, Zama D, Nastasi C, et al. Gut micro- biota trajectory in pediatric patients under- going hematopoietic SCT. Bone Marrow Transplant. 2015;50(7):992-998.
38. Galloway-Pena JR, Shi Y, Peterson CB, et al. Gut microbiome signatures are predictive of infectious risk following induction therapy for acute myeloid leukemia. Clin Infect Dis. 2020;71(1):63-71.
39. Montassier E, Gastinne T, Vangay P, et al. Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment Pharmacol Ther. 2015;42(5):515-528.
40.Taur Y, Jenq RR, Perales MA, et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood. 2014;124(7):1174-1182.
41. Jenq RR, Taur Y, Devlin SM, et al. Intestinal blautia is associated with reduced death from graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21(8):1373-1383.
42. Stein-Thoeringer CK, Nichols KB, Lazrak A, et al. Lactose drives Enterococcus expansion to promote graft-versus-host disease. Science. 2019;366(6469):1143-1149.
43.Holler E, Butzhammer P, Schmid K, et al.
Metagenomic analysis of the stool microbio- me in patients receiving allogeneic stem cell transplantation: loss of diversity is associat- ed with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus- host disease. Biol Blood Marrow Transplant. 2014;20(5):640-645.
44. Biagi E, Zama D, Rampelli S, et al. Early gut microbiota signature of aGvHD in children given allogeneic hematopoietic cell trans- plantation for hematological disorders. BMC Med Genomics. 2019;12(1):49.
45. Ilett EE, Jorgensen M, Noguera-Julian M, et al. Associations of the gut microbiome and clinical factors with acute GVHD in allo- geneic HSCT recipients. Blood Adv. 2020;4(22):5797-5809.
46.Payen M, Nicolis I, Robin M, et al. Functional and phylogenetic alterations in gut microbiome are linked to graft-versus- host disease severity. Blood Adv. 2020;4(9):1824-1832.
47. Jenq RR, Ubeda C, Taur Y, et al. Regulation of intestinal inflammation by microbiota fol- lowing allogeneic bone marrow transplanta- tion. J Exp Med. 2012;209(5):902-910.
48. Varelias A, Ormerod KL, Bunting MD, et al. Acute graft-versus-host disease is regulated by an IL-17-sensitive microbiome. Blood. 2017;129(15):2172-2185.
49. Koyama M, Mukhopadhyay P, Schuster IS, et al. MHC class II antigen presentation by the intestinal epithelium initiates graft-ver- sus-host disease and is influenced by the microbiota. Immunity. 2019;51(5):885-898.
50. Eriguchi Y, Takashima S, Oka H, et al. Graft- versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of alpha-defensins. Blood. 2012;120(1):223-231.
51.Peled JU, Devlin SM, Staffas A, et al. Intestinal microbiota and relapse after hematopoietic-cell transplantation. J Clin Oncol. 2017;35(15):1650-1659.
52. Harris B, Morjaria SM, Littmann ER, et al. Gut microbiota predict pulmonary infiltrates after allogeneic hematopoietic cell transplan- tation. Am J Respir Crit Care Med. 2016;194(4):450-463.
53. Haak BW, Littmann ER, Chaubard JL, et al. Impact of gut colonization with butyrate- producing microbiota on respiratory viral infection following allo-HCT. Blood. 2018;131(26):2978-2986.
54. Markey KA, Schluter J, Gomes ALC, et al. The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD. Blood. 2020;136(1):130-136.
55. Tamburini FB, Andermann TM, Tkachenko E, Senchyna F, Banaei N, Bhatt AS. Precision identification of diverse bloodstream pathogens in the gut microbiome. Nat Med. 2018;24(12):1809-1814.
56. Steck N, Hoffmann M, Sava IG, et al. Enterococcus faecalis metalloprotease com- promises epithelial barrier and contributes to intestinal inflammation. Gastroenterology. 2011;141(3):959-971.
57.Molina MA, Diaz AM, Hesse C, et al. Immunostimulatory effects triggered by Enterococcus faecalis CECT7121 probiotic strain involve activation of dendritic cells and interferon-gamma production. PLoS One. 2015;10(5):e0127262.
58.Ubeda C, Bucci V, Caballero S, et al. Intestinal microbiota containing Barnesiella species cures vancomycin-resistant Enterococcus faecium colonization. Infect Immun. 2013;81(3):965-973.
59.Le Roy T, Debedat J, Marquet F, et al.
Comparative evaluation of microbiota engraftment following fecal microbiota transfer in mice models: age, kinetic and microbial status matter. Front Microbiol. 2018;9:3289.
60. Smillie CS, Sauk J, Gevers D, et al. Strain tracking reveals the determinants of bacteri- al engraftment in the human gut following fecal microbiota transplantation. Cell Host Microbe. 2018;23(2):229-240.
61.Hall AB, Tolonen AC, Xavier RJ. Human genetic variation and the gut microbiome in disease. Nat Rev Genet. 2017;18(11):690- 699.
62. Abt MC, Buffie CG, Susac B, et al. TLR-7 activation enhances IL-22-mediated colo- nization resistance against vancomycin- resistant enterococcus. Sci Transl Med. 2016;8(327):327ra325.
63. Derrien M, Van Baarlen P, Hooiveld G, Norin E, Muller M, de Vos WM. Modulation of mucosal immune response, tolerance, and proliferation in mice colonized by the mucin-degrader Akkermansia muciniphila. Front Microbiol. 2011;2:166.
64. Earle KA, Billings G, Sigal M, et al. Quantitative imaging of gut microbiota spa- tial organization. Cell Host Microbe. 2015;18(4):478-488.
65.Ara T, Hashimoto D, Hayase E, et al. Intestinal goblet cells protect against GVHD after allogeneic stem cell transplantation via Lypd8. Sci Transl Med. 2020;12(550): eaaw0720.
66. Mathewson ND, Jenq R, Mathew AV, et al. Gut microbiome-derived metabolites modu- late intestinal epithelial cell damage and mit- igate graft-versus-host disease. Nat Immunol. 2016;17(5):505-513.
67.Swimm A, Giver CR, DeFilipp Z, et al. Indoles derived from intestinal microbiota act via type I interferon signaling to limit graft-versus-host disease. Blood. 2018;132 (23):2506-2519.
68. Fujiwara H, Docampo MD, Riwes M, et al. Microbial metabolite sensor GPR43 controls severity of experimental GVHD. Nat Commun. 2018;9(1):3674.
69. Kaiko GE, Ryu SH, Koues OI, et al. The Colonic Crypt Protects Stem Cells from Microbiota-Derived Metabolites. Cell. 2016;165(7):1708-1720.
70. Hanash AM, Dudakov JA, Hua G, et al. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host dis- ease. Immunity. 2012;37(2):339-350.
71. Couturier M, Lamarthee B, Arbez J, et al. IL- 22 deficiency in donor T cells attenuates murine acute graft-versus-host disease mor- tality while sparing the graft-versus- leukemia effect. Leukemia. 2013;27(7):1527- 1537.
72. Joo E, Yamane S, Hamasaki A, et al. Enteral supplement enriched with glutamine, fiber, and oligosaccharide attenuates experimental colitis in mice. Nutrition. 2013;29(3):549- 555.
73. Burrello C, Garavaglia F, Cribiu FM, et al. Therapeutic faecal microbiota transplanta- tion controls intestinal inflammation through IL10 secretion by immune cells. Nat Commun. 2018;9(1):5184.
74. Atarashi K, Tanoue T, Oshima K, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbio- ta. Nature. 2013;500(7461):232-236.
75. Campbell C, McKenney PT, Konstantinovsky D, et al. Bacterial metabo- lism of bile acids promotes generation of peripheral regulatory T cells. Nature.
haematologica | 2021; 106(8)
2051